FY2025 · ended Dec 31, 2025 · Revenue $642,000, -71.7% YoY · Filed Mar 27, 2026
BioXcel Therapeutics, Inc. (BTAIQ) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $642,000 and a net loss of $69.9 million. Free cash flow was -$57.6 million. As of Jun 30, 2026 it held $12.8 million in cash and investments and $104.5 million in total debt.
Revenue (TTM)
$742,000
-14.5% vs year-ago TTM
Net income (TTM)
$-70.86M
-39.1% vs year-ago TTM
Operating cash flow (TTM)
$-50.90M
+8.7% vs year-ago TTM
Free cash flow (TTM)
$-50.90M
+8.7% vs year-ago TTM
EPS (TTM)
$-3.16
+71.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
27.07M
+393.5% vs prior year
Net cash
$-91.61M
as of Jun 30, 2026
Operating margin
-6054.7%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BTAIQ (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1720893
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $642,000 | $2.3M | $1.4M | $375,000 | — |
| Operating income | -$50.5M | -$67.2M | -$171.8M | -$159.6M | -$106.9M |
| Net income | -$69.9M | -$59.6M | -$179.1M | -$165.8M | -$106.9M |
| Diluted EPS | -$5.73 | -$23.51 | -$98.33 | -$5.92 | -$4.05 |
| Operating cash flow | -$57.6M | -$72.0M | -$155.0M | -$135.3M | -$82.2M |
| Free cash flow | -$57.6M | — | -$155.0M | -$135.5M | -$82.6M |
| Total assets | $44.9M | $38.3M | $73.7M | $205.9M | $239.4M |
| Total liabilities | $140.4M | $131.4M | $130.2M | $129.1M | $17.8M |
| Stockholders' equity | -$95.5M | -$93.1M | -$56.5M | $76.8M | $221.7M |
| Cash and investments | $28.4M | $29.9M | $65.2M | $193.7M | $233.0M |
| Total debt | $109.7M | $102.9M | $101.4M | $94.2M | $1.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Acquisition or sale of assets, Officer or director change, Bylaw or fiscal year change
|
Oct 30, 2026 | Oct 26, 2026 |
| 8-K |
Current report
New debt, Listing notice
|
Sep 1, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Material agreement, Bankruptcy
|
Aug 28, 2026 | Aug 27, 2026 |
| 8-K |
Current report
Material agreement
|
Aug 25, 2026 | Aug 24, 2026 |
| 8-K |
Current report
Material agreement
|
Aug 24, 2026 | Aug 21, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
All 672 BioXcel Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.